Clinical Trial Update: A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial evaluating pacritinib in combination with sirolimus-based immunosuppression for the prevention of graft-versus-host disease. The study is compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Pacritinib (pacritinib)
• Sirolimus (Sirolimus)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Graft Vs Host Disease, GVHD | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-10-25